# EDGAR Filing Document

**Accession Number:** 0000879169
**File Stem:** 0001104659-25-096632
**Filing Date:** 2025-10
**Character Count:** 5487
**Document Hash:** b207145427a045d06c4d495615bbe53d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-096632.hdr.sgml**: 20251003

**ACCESSION NUMBER**: 0001104659-25-096632

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250930

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**FILED AS OF DATE**: 20251003

**DATE AS OF CHANGE**: 20251003

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** INCYTE CORP
- **CENTRAL INDEX KEY:** 0000879169
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 943136539
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12400
- **FILM NUMBER:** 251373623

**BUSINESS ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803
- **BUSINESS PHONE:** 3024986700

**MAIL ADDRESS:**
- **STREET 1:** 1801 AUGUSTINE CUT-OFF
- **CITY:** WILMINGTON
- **STATE:** DE
- **ZIP:** 19803

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE CORP
- **DATE OF NAME CHANGE:** 20030318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE GENOMICS INC
- **DATE OF NAME CHANGE:** 20000710

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INCYTE PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 19930902

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): September 30, 2025

**INCYTE CORPORATION**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br> (State or Other Jurisdiction of<br> Incorporation) | **001-12400**<br> (Commission File Number) | **94-3136539**<br> (I.R.S. Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1801 Augustine Cut-Off** |  |
| **Wilmington, DE** | **19803** |
| (Address of principal executive<br> offices) | (Zip Code) |

---

**(302) 498-6700**

(Registrant's telephone number,

including area code)

**N/A**

(Former name or former address, if

changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of exchange on which registered** |
| Common Stock, $.001 par value per share | INCY | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 30, 2025, the Board of Directors of Incyte Corporation (the "Company") appointed Thomas Tray, the Company's current Vice President, Finance and Chief Accounting Officer (principal accounting officer), to the additional position of principal financial officer, effective as of September 16, 2025. Mr. Tray, age 48, joined the Company in June 2005 as Manager, External Reporting, and has held roles of increasing responsibility, most recently prior to his current role as Vice President and Controller. Mr. Tray received his B.S. in Accounting from Mount Saint Mary's University and has an Executive MBA in Pharmaceutical Marketing from Saint Joseph's University.

There are no arrangements or understandings between Mr. Tray and any other persons pursuant to which he was appointed as principal financial officer. Mr. Tray has no family relationships with any of the Company's directors or executive officers, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: October 3, 2025 |  |  |
|  | INCYTE CORPORATION | INCYTE CORPORATION |
|  | By: | /s/ Sheila A. Denton |
|  |  | Sheila A. Denton |
|  |  | Executive Vice President and General Counsel |

---